Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.40 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28812970 | 0.90 | S1PR1 (0.43) | S1PR1S1PR3HDAC4HDAC1HDAC6 | |
| SCHEMBL405411 | 0.81 | LMNA (0.45) | S1PR1S1PR3HDAC4HDAC6GABRA5 | |
| SCHEMBL1225874 | 0.81 | ESR1 (0.46) | S1PR1S1PR3GABRA5KDM4ELMNA | |
| SCHEMBL27853872 | 0.80 | ESR1 (0.44) | S1PR1S1PR3GABRA5KDM4ELMNA | |
| SCHEMBL409574 | 0.80 | PTPN1 (0.46) | GABRA5KDM4EKDM6BKDM4AKDM5C | |
| SCHEMBL27876332 | 0.78 | TRPV1 (0.41) | KDM4ETRPV1L3MBTL1 | |
| SCHEMBL10111594 | 0.78 | GABRA5 (0.48) | GABRA5KDM4EKDM6BKDM4AKDM5C | |
| SCHEMBL404322 | 0.78 | PTPN1 (0.43) | S1PR1S1PR3HDAC4HDAC1HDAC6 | |
| SCHEMBL27837002 | 0.78 | ESR1 (0.41) | S1PR1S1PR3HDAC4HDAC1HDAC6 | |
| SCHEMBL1226119 | 0.74 | ESR1 (0.44) | S1PR1S1PR3GABRA5KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404672-B2 | Substituted heterocyclic compounds | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| CN-102686571-A | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | disclosed |
| CN-102548989-A | Sphingosine-1-phosphate receptor agonists | BRISTOL MYERS SQUIBB CO | 2012-07-04 | — | — | CN | disclosed |
| EP-2462139-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2389377-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Bristol-Myers Squibb Company (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8038731-B2 | hair dyes contains naphthylimide thiol or disulphide groups; resistant and visible lightening effect on dark keratin fibres; cosmetics | L'OREAL S.A. (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| WO-2011017578-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011017578-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085582-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885HDAC4 2686/4885 |
| US-20120022041-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | S1PR1, S1PR4, S1PR3 | S1PR1 1/4885S1PR3 3/4885HDAC4 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.